Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Methyl Carbamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Carbamate SCHEMBL27839791 | 0.89 | — | — | |
| Methyl Carbamate SCHEMBL28142916 | 0.89 | — | — | |
| Methyl Carbamate SCHEMBL27455257 | 0.89 | — | — | |
| Methyl Carbamate SCHEMBL788713 | 0.89 | ALDH1A1 (0.50) | — | |
| Methyl Carbamate SCHEMBL4140 | 0.89 | — | — | |
| Methyl Carbamate SCHEMBL27967372 | 0.86 | ACHE (0.50) | — | |
| Oxalic Acid SCHEMBL28068121 | 0.86 | LDHA (0.44) | — | |
| Methyl Carbamate SCHEMBL15688513 | 0.85 | — | — | |
| Methyl Carbamate SCHEMBL28494384 | 0.85 | — | — | |
| Methyl Carbamate SCHEMBL3465204 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1021 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000788-A1 | METHOD FOR DRY POWDER COATING CAPSULES | NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) | 2022-01-06 | — | — | US | claimed |
| EP-3813801-A2 | EXTENDED RELEASE OSMOTIC TABLET DOSAGE FORM COMPRISING METFORMIN AND SITAGLIPTIN | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2021-05-05 | — | — | EP | claimed |
| US-20200222330-A1 | METHOD FOR DRY POWDER COATING CAPSULES | POWDER PHARMA COATING INC. (CA) | 2020-07-16 | — | — | US | claimed |
| US-20190099378-A1 | METHOD FOR DRY POWDER COATING CAPSULES | NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) | 2019-04-04 | — | — | US | claimed |
| US-20190099377-A1 | METHOD FOR DRY POWDER COATING OSMOTIC DRUG DELIVERY SYSTEM | NINGBO WESTON POWDER PHARMA COATINGS CO., LTD. (CN) | 2019-04-04 | — | — | US | claimed |
| CN-109200028-A | A kind of dry coating process preparing drug osmotic pump preparation | 宁波西敦医药包衣科技有限公司 | 2019-01-15 | — | — | CN | claimed |
| CN-108785270-A | A kind of method of dry powder coated capsule preparation | 宁波西敦医药包衣科技有限公司 | 2018-11-13 | — | — | CN | claimed |
| EP-2305624-B1 | Self-degradable explosive device | MAXAMCORP HOLDING SL (ES) | 2017-09-27 | — | — | EP | claimed |
| CN-103284974-B | Benzene ring nonyl ester double-layer osmotic pump controlled-release tablet and preparation method thereof | WUHAN GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND, PLA (CN) | 2016-01-20 | — | — | CN | claimed |
| US-9149439-B2 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2015-10-06 | — | — | US | claimed |
| WO-2003092660-A1 | MONOCOMPARTMENT OSMOTIC CONTROLLED DRUG DELIVERY SYSTEM | RANBAXY LABORATORIES LIMITED (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030096001-A1 | Encapsulation products and method of controlled release of fluoxetine or mesalamine | CAPRICORN PHARMA INC. | 2003-05-22 | — | — | US | claimed |
| WO-2003011205-A2 | ENCAPSULATION PRODUCTS FOR CONTROLLED OR EXTENDED RELEASE | CAPRICORN PHARMA, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020044962-A1 | Encapsulation products for controlled or extended release | CHERUKURI S RAO (US) | 2002-04-18 | — | — | US | claimed |
| US-6365185-B1 | ORAL TABLET FOR DELIVERING BENEFICIAL AGENT TO MAMMAL COMPRISING CORE COMPARTMENT HAVING BENEFICIAL AGENT SURROUNDED BY UNITARY SELF-DESTRUCTING SHELL COMPRISING PLURALITY OF DISINTEGRANT PARTICLES DISPERSED WITHIN SEMIPERMEABLE MATRIX | UNIVERSITY OF CINCINNATI | 2002-04-02 | — | — | US | claimed |
| EP-1027888-A2 | Osmotic system for delivery of solid amorphous dispersions of drugs | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| US-5612059-A | CELLULOSE DERIVATIVE, DRUG DELIVERY | PFIZER INC. (US) | 1997-03-18 | — | — | US | claimed |
| US-5458887-A | OF AN OSMOTIC CORE CONTAINING A DRUG AND A WATER SWELLABLE COMPONENT AND A WATER RESISTANT POLYMER COATING CONTAINING A COMPOUND WHICH DISSOLVES IN GASTROINTESTINAL FLUID | ANDRX PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | claimed |
| EP-0326727-A1 | Sustained release implant and method for preparing same | INTERNATIONAL MINERALS AND CHEMICAL CORPORATION (US) | 1989-08-09 | — | — | EP | claimed |
| US-4761289-A | Sustained release implant and method for preparing same | INTERNATIONAL MINERALS & CHEMICAL CORP. (US) | 1988-08-02 | — | — | US | claimed |